The FDA issued a second, expanded recall of duloxetine after higher than acceptable levels of a cancer-causing chemical were ...

Australian-led research is unlocking new ways for immunotherapy to better target cancer. Cancer immunotherapy has ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

A treatment for a rare type of cancer has been accepted for use on the NHS in Scotland. The Scottish Medicines Consortium ...

The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...

AstraZeneca’s Imfinzi (durvalumab) has been granted Priority Review by the FDA for the treatment of muscle-invasive bladder cancer (MIBC), pote ...

US FDA grants priority review status to AstraZeneca’s sBLA for Imfinzi to treat patients with muscle-invasive bladder cancer: Cambridge, UK Saturday, December 7, 2024, 09:00 Hrs ...